Clinical Trials Administrator Archives – August 1, 2006
August 1, 2006
View Archives Issues
-
Development delays lead to new trends in clinical trials industry
In 2005, major pharmaceutical companies are estimated to have spent $45-$50 billion on research and development. Yet only 17 drugs were approved for marketing by the FDA, says Dan McDonald, vice president of Thomson CenterWatch in Boston. -
Overseas trials: The trend has limitations
Clinical trials in the United States have trouble recruiting subjects, completing on time, and maintaining high quality and efficiency, and these problems are why major pharmaceutical companies and other sponsors are offering more business to international research organizations, experts say. -
Recruiting: A picture's worth a thousand words
Sponsors and clinical trial sites increasingly are turning to multimedia material for both recruiting subjects and for explaining particulars of a study during the informed consent process. -
What do clinical trial participants want?
Researchers increasingly are told they need to involve participants in clinical trial design, but most would agree this is a difficult ideal to follow. -
Master's degrees are gaining acceptance
Master's degree programs in clinical research administration or management, as well as certificate programs, are gaining ground as training vehicles for people who work in health care or another professional field and would like to switch to clinical trials and research. -
News Briefs
Community speakers bureau launched; FDA warns against use of unapproved drug products